Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q1 2024 · 10-Q
Revenue$2.40M$2.40M−5.1% vs Q1 2023 Net Income-$16.94M-$16.94MN/M vs Q1 2023 EPS Diluted-$0.24-$0.24N/M vs Q1 2023 Operating Income-$18,931,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Free Cash Flowderived-$20,950,000N/M Margins · derivedOperating margin-789.4%+394.0 pt vs Q1 2023
Net margin-706.5%+407.5 pt vs Q1 2023
ended Mar 31, 2024 · filed May 7, 2024 · 37 d after period end